stockrow
Saturday 7 November 2026
Export SVRA’s income statement to Excel — free account
Savara Inc.
SVRA Healthcare Biotechnology
- EPS
- −14.3%
- Free cash flow
- −14.1%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
4.83
0.45
+10.27%
Follow SVRA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 0 | — | — | — | 0 | — | — | — | — | — | — | (10.5%) | 2 | 80 | 202 | +960.6% | |
| Gross margin, % | 100.00 | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 | 0.00 | — | — | — | 0.00 | (100.0) pt | ||||||
| EBT | (11) | (33) | (69) | (78) | (50) | (43) | (38) | (55) | (96) | (119) | (139) | +29.9% | ||||||
| EBT margin, % | (2,820.00) | 0.00 | 0.00 | 0.00 | (19,305.45) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +2,820.0 pt | ||||||
| Net income | (11) | (30) | (62) | (78) | (50) | (43) | (38) | (55) | (96) | (119) | (139) | +30.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (5.57) | (1.76) | (1.85) | (1.95) | (0.84) | (0.32) | (0.25) | (0.33) | (0.48) | (0.53) | (0.58) | (23.0%) | ||||||
| Cash flow | (4.27) | (1.61) | (1.18) | (1.13) | (0.67) | (0.30) | (0.23) | (0.31) | (0.45) | (0.45) | (0.44) | (22.0%) | ||||||
| Capex | 0.00 | (0.03) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (33.8%) | ||||||
| Free cash flow | (4.27) | (1.64) | (1.18) | (1.13) | (0.67) | (0.30) | (0.23) | (0.31) | (0.45) | (0.45) | (0.44) | (22.0%) | ||||||
| Book value | 4.07 | 6.81 | 3.25 | 2.54 | 1.09 | 1.08 | 0.71 | 0.85 | 0.87 | 0.91 | 0.57 | (15.3%) | ||||||
| Shares, m | 2 | 18 | 33 | 40 | 59 | 134 | 153 | 165 | 198 | 222 | 236 | +69.2% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | — | — | — | 0.00 | — | — | — | — | — | 0.00 | 0.0 | |||||
| P/S | 0.00 | — | — | — | 0.00 | — | — | — | — | — | 0.00 | 0.0 | ||||||
| P/B | 0.00 | — | — | — | 1.06 | — | — | — | — | — | 8.53 | 0.5 | ||||||
| EV/Sales | 0.00 | — | — | — | 0.00 | — | — | — | — | — | 0.00 | 0.0 | ||||||
| EV/FCF | (1.82) | — | — | — | (0.28) | — | — | — | — | — | (9.89) | (1.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (8) | (28) | (39) | (45) | (40) | (40) | (35) | (51) | (89) | (101) | (110) | +31.9% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +11.9% | ||||||
| Free cash flow | (8) | (29) | (39) | (45) | (40) | (40) | (35) | (51) | (89) | (101) | (111) | +31.9% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 11 | 92 | 106 | 113 | 77 | 150 | 123 | 155 | 187 | 221 | 161 | +39.4% | |||||
| Net debt | (9) | (79) | (86) | (97) | (57) | (136) | (100) | (136) | (170) | (206) | (143) | +41.8% | ||||||
| Shareholders’ equity | 8 | 119 | 108 | 102 | 64 | 144 | 108 | 140 | 171 | 203 | 144 | +43.3% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (26.50) | (32.65) | (39.44) | (54.19) | (42.42) | (31.36) | (24.12) | (34.47) | (49.11) | (50.97) | (78.28) | (24.5) pt | |||||
| ROIC | 0.00 | (46.42) | (199.35) | (978.23) | (412.04) | (288.58) | (304.19) | (852.18) | (3,704.62) | 0.00 | (12,213.18) | 0.0 pt | ||||||
| ROE | 183.83 | (73.78) | (54.07) | (74.48) | (59.75) | (41.19) | (30.24) | (44.08) | (61.50) | (63.45) | (105.48) | (247.3) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 9 | 24 | 34 | 40 | 27 | 22 | 28 | 37 | 59 | 70 | — | +25.6% | |||||
| Revenue/emp, $m | 0.04 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2020 · latest quarter Dec 2020 · fundamentals updated 25 Oct 2026
Savara Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| IMTX Immatics N.V. | $924.8M | — (loss-making) | — (loss-making) | +97.71% (above 0%: growing) | n/m | −44.41% (below 0%: shrinking) | 100.00% | (734.95%) | Compare |
| MLTX MoonLake Immunotherapeutics | $919.2M | — (loss-making) | — | — | n/m | −1.89% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ODTX Odyssey Therapeutics, Inc. | $907.3M | — (loss-making) | — | — | n/m | — | 100.00% | 0.00% | Compare |
| SVRA Savara Inc. | $899.9M | — (loss-making) | — (loss-making) | — | n/m | −14.05% (below 0%: shrinking) | 0.00% | 0.00% | |
| JBIO Jade Biosciences, Inc. | $896.7M | — (loss-making) | — | — | n/m | −115.11% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CTY City Therapeutics, Inc | $882.9M | — | — | — | — | — | — | — | Compare |
| ORIC Oric Pharmaceuticals, Inc. | $880.0M | — (loss-making) | — | — | n/m | −3.42% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GLUE Monte Rosa Therapeutics, Inc. | $874.5M | — (loss-making) | — (loss-making) | +325.80% (above 0%: growing) | n/m | −142.63% (below 0%: shrinking) | 100.00% | (3.57%) | Compare |
| PHAR Pharming Group N.V. Sponsored ADR | $870.6M | 34.2× | — (loss-making) | +20.86% (above 0%: growing) | +190.91% (above 0%: growing) | +0.42% (above 0%: growing) | 86.90% | 25.34% | Compare |
| Median of peers | $889.8M | — | — | +97.71% | — | −23.91% | 86.90% | 0.00% |
Pay and ownership Proxy statement filed 24 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 4.85m | 9.89m | 196.00 |
| 2024 | 4.91m | 3.97m | 65.00 |
| 2023 | 3.76m | 5.66m | 303.00 |
Ownership
Directors and executive officers, together
5.30%
Persons and entities affiliated with New Enterprise Associates
11.94%
Entities affiliated with Bain Capital Life Sciences, L.P.
9.99%
Persons and entities affiliated with Venrock Healthcare Capital Partners III, LP
9.99%
Persons and entities affiliated with Farallon Capital Management, LLC
6.82%
Persons and entities affiliated with Deerfield Mgmt, L.P.
6.62%
Persons and entities affiliated with TCG Crossover
6.03%
Blackrock, Inc.
5.35%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement